Cortagen
AEDP · Ala-Glu-Asp-Pro · brain cortex tetrapeptide
Last updated
At a glance
Overview
Cortagen Overview: A Cortex-Derived Bioregulator for Cognition and Nerve Repair#
Cortagen (AEDP, Ala-Glu-Asp-Pro) is one of the Khavinson short-peptide bioregulators — a four-residue sequence isolated from the active core of Cortexin, the bovine cerebral-cortex preparation used in Russian neurology for decades. It sits in the same family as Epitalon, Pinealon and Vilon, but the tissue targeting is specifically cortical and peripheral-neural: upregulation of BDNF and NGF, synaptic-scaffold protein expression, and a documented 27% increase in axonal growth rate in the foundational sciatic-nerve regeneration study.
The community runs it for three things — baseline cognitive repair and neuroplasticity, post-concussion / post-TBI recovery, and peripheral-nerve injury work (entrapments, post-surgical nerve healing, diabetic-style neuropathy). It is not a "feel-it" acute nootropic like Semax or Selank; it is the chronic substrate those compounds build on. Looksmaxxers and longevity-stack users rotate it with Epitalon and Pinealon on a Khavinson-school cadence. Lifters managing a brachial-plexus or ulnar issue stack it with BPC-157. High-output knowledge workers use it as a 20-day cortical tune-up twice a year.
"The axonal growth rate increased by 27% and conduction velocity by 40% under the action of cortagen, compared with the control group." — Turchaninova et al., Bulletin of Experimental Biology and Medicine (2000)
What makes Cortagen interesting mechanistically is that a 430 Da tetrapeptide is small enough to cross into the nucleus and bind double-stranded DNA directly — the effect is transcriptional, which is why the biology persists 2–4 weeks after a course ends and why the protocol is pulsed (20–28 days on, 8+ weeks off) rather than run continuously. The sections below cover documented Cortagen dosage ranges, the 20-day pulse protocol, stacking with Semax / Selank / BPC-157 and the broader Khavinson rotation, side-effect profile, and the most common protocol mistakes — including under-dosing based on the rat nerve-injury study and the over-stimulation trap at the 2 mg evening tier.
How Cortagen works
Direct DNA Binding and Epigenetic Modulation#
Cortagen (Ala-Glu-Asp-Pro, AEDP) is a Khavinson-class short peptide — small enough (~430 Da, four residues) to cross plasma and nuclear membranes without a transporter and bind directly to double-stranded DNA. Rather than acting through a surface receptor, it intercalates into specific DNA motifs and histone complexes, decondensing heterochromatin and unmasking age-silenced transcriptional regions. This is the defining mechanism shared across the AEDx bioregulator family — Cortagen's tissue-specificity comes from which gene sets the AEDP sequence preferentially activates.
"Short peptides possess the ability to penetrate into the nucleus, where they specifically bind to double-stranded DNA and histones, modulating gene expression." — Khavinson V., Advances in Gerontology, 2014
The practical consequence: effects persist long after plasma clearance (minutes). Transcriptional programs, once nudged, run for 2–4 weeks after a course ends — which is why the protocol is pulsed (20–28 days on, ≥8 weeks off), not continuous.
Cortex-Targeted Gene Expression#
Microarray profiling shows Cortagen is not a blunt instrument. In mouse tissue, it modulated a defined set of ~110 transcripts with a signature distinct from Vilon, Epitalon, and melatonin — confirming that each Khavinson tetrapeptide hits a different gene panel.
"Cortagen influenced the expression of 110 genes, showing significant regulation with up to 5.42-fold increase and 2.86-fold decrease in transcripts." — Anisimov SV, Khavinson VK, Anisimov VN., Neuro Endocrinology Letters, 2004
In cortical tissue specifically, the downstream protein output includes BDNF, NGF, PSD-95, synaptophysin, and synapsin-1 — the trophic factors and synaptic scaffolding that underwrite neuroplasticity. This is the molecular basis for the cognitive and nootropic endpoints users care about: focus, memory consolidation, and recovery of synaptic density after stress, sleep deprivation, or AAS-related neuroinflammatory load.
Peripheral Nerve Regeneration#
Cortagen's most concrete preclinical signal is axonal. In a rat sciatic-nerve transection/suture model, a 10-day IM course at 10 µg/kg accelerated regeneration measurably across two independent endpoints:
"The axonal growth rate increased by 27% and conduction velocity by 40% under the action of cortagen, compared with the control group." — Turchaninova LN et al., Bulletin of Experimental Biology and Medicine, 2000
Practical translation: this is the mechanism physique-focused users lean on for entrapment neuropathies (ulnar, brachial plexus, sciatic irritation) and post-surgical nerve recovery. It also explains why Cortagen stacks logically with BPC-157 — BPC-157 handles the soft-tissue and vascular side of the repair; Cortagen accelerates the neural side.
Ischemic Neuroprotection and Metabolic Rescue#
Under conditions of cerebral hypoperfusion, Cortagen supports mitochondrial function and antioxidant capacity in cortical tissue, correcting the neurological and biochemical deficits that define ischemic injury.
"Cortagen contributed to amelioration of neurological and metabolic disturbances under conditions of cerebral ischemia and potentiated the efficacy of ischemic preconditioning." — Zarubina IV, Shabanov PD., Bulletin of Experimental Biology and Medicine, 2016
For the community this matters in two contexts: post-concussion / post-TBI recovery protocols (often paired with Cerebrolysin in Eastern European clinical practice), and as an on-cycle cortical buffer for users running heavy stimulants or high-dose AAS where cerebrovascular and oxidative stress are elevated.
Motor / Arousal Signal Without Anxiogenic Shift#
Cortagen produces a measurable behavioral stimulation without the anxiety-axis disruption seen with some nootropics and cholinergics.
"Cortagen administration resulted in a marked enhancement of motor activity, without affecting anxiety-related behavioral scores in mice." — Adriani W et al., The Open Neuropsychopharmacology Journal, 2009
This is the mechanistic fingerprint of the subjective "clean activation" community users report — and the reason AM dosing is standard. At the 2 mg tier the arousal signal is strong enough to disrupt sleep if administered in the evening. Paired with a same-day acute nootropic (Semax, Selank), Cortagen provides the chronic substrate while the intranasal peptide handles the acute focus signal — the two mechanisms layer cleanly because they operate on different timescales.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 500–1000 mcg | Once daily | Documented entry-level range |
| Mid | 1000–2000 mcg | Once daily | Most commonly studied range |
| High | 1500–2000 mcg | Once daily | AM dosing is the default — evening administration at the 2mg tier can be over-stimulating and disrupt sleep. Protocols are pulsed, not continuous: 20–28 day course, then off for 8+ weeks. |
Cycle length & outcomes
Documented cycle
2–4 weeks
Plateau after
4 wks
Cycle Structure: Pulse, Don't Cruise#
Cortagen is a bioregulator, not a daily peptide. The community protocol is short courses with long washouts — the epigenetic and neurotrophic signal persists 2–4 weeks after the last injection, so continuous dosing wastes vial and blunts responsiveness. Two to three 20–28 day courses per year is the Khavinson-school cadence.
Dose Ladder by Goal#
| Goal | Cycle Length | Daily Dose | Route |
|---|---|---|---|
| Peripheral nerve repair (entrapment, post-surgical) | 10–14 days | 1000mcg | SubQ or IM |
| Cognitive / focus baseline | 20–28 days | 1000mcg week 1–2 → 2000mcg week 3–4 | SubQ or intranasal |
| Post-concussion / TBI adjunct | 20 days | 1000–2000mcg | SubQ (intranasal split preferred for CNS targeting) |
| Longevity / Khavinson rotation | 20 days, 2×/year | 1000–1500mcg | SubQ |
| On-cycle neuroprotection (alongside AAS or heavy stim use) | 20–28 days | 1000–1500mcg | SubQ |
Loading & Titration#
No loading phase is required in the anabolic-peptide sense, but the community convention is a half-dose first week (1000mcg) before stepping to the full 2000mcg tier. The rationale is tolerability — headaches on initiation at 2mg are the most commonly reported subjective effect and usually resolve within the first week. Stepping in avoids that window entirely.
"Cortagen administration resulted in a marked enhancement of motor activity, without affecting anxiety-related behavioral scores in mice." — Adriani et al., Open Neuropsychopharmacology Journal (2009)
That motor-stimulation signal is why AM dosing is the default. Evening administration at the 2mg tier can feel over-stimulating and fragment sleep. For intranasal users running a Semax/Selank-style focus stack, Cortagen goes in with the morning dose and nothing moves to evening.
Onset Timing#
Cortagen is a chronic substrate compound, not an acute signal. Do not expect a Semax-style "feel-it" hit within 30 minutes. Realistic onset:
- Peripheral nerve / regeneration endpoints: objective changes (conduction velocity, reduced paresthesia) emerge across the 10–14 day course and continue improving for 2–4 weeks after. The original rat work showed a 27% increase in axonal growth rate and 40% increase in conduction velocity at 10 days of 10 µg/kg IM dosing.
"The axonal growth rate increased by 27% and conduction velocity by 40% under the action of cortagen, compared with the control group." — Turchaninova et al., Bulletin of Experimental Biology and Medicine (2000)
- Cognitive endpoints: subjective improvement in word recall, mental stamina, and stress resilience typically reported by day 7–10, with the full effect consolidating across weeks 3–4 and persisting through the washout.
- Post-course persistence: 2–4 weeks of residual benefit is standard, consistent with the transcriptional mechanism.
"Short peptides possess the ability to penetrate into the nucleus, where they specifically bind to double-stranded DNA and histones, modulating gene expression." — Khavinson, Advances in Gerontology (2014)
Because the output is at the gene-expression level, the "half-life" that matters is the downstream protein and chromatin turnover, not plasma clearance.
Stacking Within a Cycle#
- Cognitive stack: Cortagen as the chronic substrate + Semax 300mcg intranasal or Selank 250–500mcg intranasal as the acute signal. Cortagen builds the soil; Semax/Selank are the same-day weather.
- Recovery stack: Cortagen + BPC-157 (250–500mcg SubQ) ± TB-500 for combined neural and soft-tissue repair. Particularly relevant for brachial-plexus, ulnar entrapment, or post-surgical nerve work where BPC-157's vascular/tendon signal complements Cortagen's axonal growth signal.
- Khavinson rotation: Cortagen 20 days → washout → Epitalon (AEDG) 20 days → washout → Pinealon (EDR) 20 days. Two full rotations per year. Each tetra/tripeptide unlocks a different tissue-specific gene set, so rotation hits cortex, pineal/telomere axis, and generalized CNS antioxidant programs in turn.
- On-cycle buffer: Cortagen runs cleanly alongside AAS cycles with no documented interaction — purely additive on neurotrophic and antioxidant pathways.
"Cortagen contributed to amelioration of neurological and metabolic disturbances under conditions of cerebral ischemia and potentiated the efficacy of ischemic preconditioning." — Zarubina & Shabanov, Bulletin of Experimental Biology and Medicine (2016)
Bloodwork & Monitoring#
Cortagen does not require dedicated bloodwork. It has no documented endocrine, HPTA, lipid, or hepatic activity — no PCT, no estrogen management, no hematocrit concern. Users running it alongside an AAS cycle keep the standard panel (lipids, LFTs, hematocrit, CBC, hs-CRP) on normal cycle cadence; Cortagen itself doesn't change what gets drawn or when.
For nerve-repair protocols, the meaningful monitoring is functional: grip strength, two-point discrimination, symptom mapping. For cognitive protocols, subjective tracking (sleep quality, word recall, mental stamina) across the 20–28 day course is what the community relies on.
Post-Cycle#
No taper. No PCT. The course ends on day 20–28 and the washout begins — minimum 8 weeks before the next Cortagen course, longer if rotating through Epitalon and Pinealon. The gene-expression signature from a single course (110 genes modulated up to 5.42-fold) is doing work for weeks after the last injection, and re-dosing into that window is the most common mistake in the bioregulator space.
Risks & mistakes
Common (most users)#
- Injection-site erythema or tenderness — standard SC peptide profile. Rotate sites (abdomen, delt, thigh) and allow the reconstituted solution to warm to skin temperature before administration.
- Mild headache on initiation — most commonly reported at the 2 mg/day tier, consistent with the motor-stimulation signal seen in rodent behavioral work (Adriani et al. 2009). Usually resolves within the first 5–7 days. Mitigation: start at 1000 µcg for weeks 1–2 and titrate up, and keep dosing to the morning.
- Transient nasal dryness or mild burning (intranasal route) — typically from the bacteriostatic water vehicle, not the peptide. Dividing the dose between nostrils and spacing from other intranasal compounds (Semax, Selank) by at least 10 minutes resolves it.
- Mild over-stimulation / racing thoughts if dosed late in the day — AM administration is the default for this reason. If an evening dose is unavoidable, drop back to the 1 mg tier.
"Cortagen administration resulted in a marked enhancement of motor activity, without affecting anxiety-related behavioral scores in mice." — Adriani et al., Open Neuropsychopharmacol. J. 2009
Uncommon (dose-dependent or individual)#
- Sleep disruption at the 2 mg tier — back off to 1–1.5 mg or move dosing earlier in the day. The motor-activation signal from the rodent literature is the likely substrate.
- Irritability or edge — rare at community doses but reported when Cortagen is stacked with Semax, Selank, or stimulants without a break-in. Stagger introduction of new compounds by at least a week.
- Blunted acute response in later courses — the epigenetic effects of a course persist 2–4 weeks post-cessation (Khavinson 2014). Running Cortagen continuously degrades the subjective signal; 8+ weeks off between courses restores it.
- Vivid dreams — occasionally reported in community write-ups, not documented in the published literature. Self-limiting.
Rare but serious#
- Allergic / hypersensitivity reactions — theoretical for any synthetic peptide. Warning signs are spreading urticaria, facial or airway swelling, or systemic rash beyond the injection site. Discontinue immediately and do not re-challenge.
- Unexplained neurological symptoms (persistent severe headache, visual changes, focal weakness) during a course — discontinue and evaluate. No such events are reported in the Cortagen literature, but the symptom overlap with unrelated pathology means these warrant a pause, not a wait-and-see.
- Persistent injection-site induration or abscess formation — points to sterile-technique or contamination issues, not the peptide itself. Discard the vial and restart with a fresh reconstitution.
Hard contraindications#
- Active malignancy. Cortagen modulates gene expression across 110+ transcripts and promotes cell differentiation and proliferation (Anisimov, Khavinson & Anisimov 2004). Any active or recently treated cancer is an absolute exclusion until long-term human oncology data exist.
- Pregnancy and lactation. No reproductive-toxicology data. Excluded by default.
- Known peptide hypersensitivity, including prior reaction to Cortexin or other Khavinson bioregulators.
- Pediatric use. No safety envelope defined; restrict to adults.
"Short peptides possess the ability to penetrate into the nucleus, where they specifically bind to double-stranded DNA and histones, modulating gene expression." — Khavinson, Advances in Gerontology 2014
This mechanism is also the reason active malignancy is a hard line — transcriptional modulators do not belong near uncontrolled cell division.
Gender-specific and PCT considerations#
Cortagen is non-hormonal. It has no documented HPTA, aromatase, or androgen-receptor activity across the published preclinical literature. No PCT is required and no sex-specific dosing adjustment applies — the same 500–2000 µcg range is used across the subject pool. Female users running it for cognitive or neuroregenerative indications follow identical protocols to male users.
Pregnancy and lactation remain hard contraindications on a no-data basis, not on any identified mechanism of harm. For anyone planning conception in the near term, the conservative approach is to complete a course and allow the standard 8-week washout before attempting, given that transcriptional effects persist 2–4 weeks post-course.
FAQ — Cortagen
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy Cortagen, 20mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Cortagen
Research & citations
5 studies cited on this page.
Conclusion
Cortagen is a standout nootropic and neural repair peptide in the Khavinson bioregulator class — uniquely positioned for protocols aiming at cortical plasticity, nerve regeneration, and high-output cognitive maintenance.
Key takeaways:
- Typical daily dose: 1000–2000 µg, subcutaneously, once daily, defaulting to AM administration; avoid evening dosing to minimize sleep disruption
- Cycle structure: 20–28 day pulse, then off for at least 8 weeks; continuous use is not supported
- Route preference: subcutaneous is community standard; intranasal is favored for CNS-specific protocols
- Stacks cleanly with Semax or Selank for acute focus, and with BPC-157 or TB-500 in nerve-injury and recovery protocols
- Headline benefit: durable cognitive and neurotrophic effects through direct gene-expression modulation — enhanced axonal growth and repair, with a notably benign side-effect profile
- Hard contraindications: active malignancy, pregnancy, lactation, and known peptide hypersensitivity only
For any protocol targeting recovery after neural injury, cognitive optimization, or structured longevity, Cortagen provides a well-evidenced and user-friendly tool in the bioregulator toolkit.